Interleukin-17 (IL-17) Inhibitors in the Treatment of Plaque Psoriasis: A Review.

Interleukin-17 (IL-17) Inhibitors in the Treatment of Plaque Psoriasis: A Review. Skin Therapy Lett. 2015 Feb;20(1):1-5 Authors: Gooderham M, Posso-De Los Rios CJ, Rubio-Gomez GA, Papp K Abstract Acting on keratinocytes to produce antimicrobial peptides and chemokines, which in turn attract neutrophils and other inflammatory cells, interleukin-17 (IL-17) is believed to be a potent driver of plaque psoriasis. Its proinflammatory characteristics make IL-17 an attractive therapeutic target for addressing immune dysregulation. This review examines the role of IL-17 in the pathogenesis of plaque psoriasis and the potential implications of its inhibition. The efficacy and safety results from Phase 2 and 3 trials with monoclonal antibodies targeting IL-17RA (brodalumab), and IL-17A (ixekizumab and secukinumab) validate IL-17 as an effective therapeutic target for the treatment of plaque psoriasis. PMID: 25807214 [PubMed - in process]
Source: Skin Therapy Letter - Category: Dermatology Authors: Tags: Skin Therapy Lett Source Type: research

Related Links:

Conclusions: Although heterogeneity across cohorts may explain some medication utilization differences, ustekinumab was associated with lower discontinuation and greater persistence and adherence. PMID: 31714168 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
Conditions:   Rheumatoid Arthritis;   Psoriatic Arthritis;   Crohn's Disease;   Axial Spondyloarthritis;   Plaque Psoriasis Intervention:   Drug: Pharmacokinetics of certolizumab pegol Sponsor:   UCB Biopharma S.P.R.L. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
CONCLUSION: The retrieved trials have deficiencies that make it difficult to reliably evaluate the efficacy, safety, and utility of mAb/FP for children and adolescents with chronic inflammatory diseases. mAb/FP nonetheless represent a treatment option to be considered in case conventional immune-modulating drugs are ineffective. Researcher-initiated, high-quality trials and manufacturer-independent, systematic long-term evaluations of adverse effects (e.g., tumors) are sorely needed. PMID: 31711560 [PubMed - in process]
Source: Deutsches Arzteblatt International - Category: General Medicine Tags: Dtsch Arztebl Int Source Type: research
Conclusions The long-term risks of autoimmune disorders are significantly higher in patients with allergic diseases. Allergic diseases and autoimmune disorders show age- and sex-related clustering patterns.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Asthma and allergy Original Articles: Asthma and allergy Source Type: research
In conclusion, the PEST-bp questionnaire proved to be suitable as a screening tool for PsA in patients with psoriasis. Elevated PEST-bp scores are associated with decreased patient quality of life.
Source: Archives of Dermatological Research - Category: Dermatology Source Type: research
In conclusion, immunogenicity data of biosimilars or biosimilar candidates for TNFα or CD20 inh ibitors were collected in trials that varied in design and procedures for ADAb/nAb detection. In general, immunogenicity parameters of biosimilars are similar to those of their reference products.
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
TUESDAY, Nov. 12, 2019 -- For patients with psoriatic arthritis (PsA), the age of psoriasis onset determines whether arthritis or psoriasis starts first, according to a study presented at the annual meeting of the American College of Rheumatology,...
Source: - Pharma News - Category: Pharmaceuticals Source Type: news
Electronic health records (EHRs) are promising tools for routine care. These applications might not only enhance the interaction between patient and physician but also support therapy management. This is cruci...
Source: BMC Medical Informatics and Decision Making - Category: Information Technology Authors: Tags: Research article Source Type: research
Abstract The advent of biologic agents that target cytokines central to the psoriatic disease cascade have revolutionised the treatment of moderate to severe psoriasis. Methotrexate (MTX) remains the recommended first-line conventional systemic treatment for moderate to severe psoriasis.1 This is due to its well established efficacy, safety profile and low cost1 . Across published data, MTX demonstrates a PASI 75 of approximately 40% at weeks 12-162 , with a median drug survival of 1.8 years.3 The cost of oral MTX is less than 1%, and subcutaneous (SC) MTX less than 10% of that of the cheapest biologic agent in th...
Source: The British Journal of Dermatology - Category: Dermatology Authors: Tags: Br J Dermatol Source Type: research
AbstractPurpose of ReviewAnkylosing spondyloarthritis (AS) is a chronic inflammatory disease that involves the axial joints and entheses. Extra-spinal manifestations such as anterior uveitis, psoriasis, and colitis also occur frequently. This review on the pathogenesis of AS includes an update on the recent discoveries within the field.Recent FindingsHLA-B*27 is still considered of major importance in the pathogenesis, and it has recently been shown to profoundly affect the gut microbiome and its metabolites and the handling of bacteria during infection. Biochemical and biophysical properties of HLA-B*27 influence its abil...
Source: Current Rheumatology Reports - Category: Rheumatology Source Type: research
More News: Dermatology | Psoriasis | Skin